The Problem: Comparative Effectiveness studies burst on to the health policy scene, providing new hope they’d help make health care more affordable and help clinicians deliver care of higher quality. Our Engagement: We were engaged to patient groups understand the territory so they could engage in the variety of policy-setting meetings underway in both the
The Problem: The Institute of Medicine, National Academy of Sciences, was asked to review Department of Defense research programs to protect members of the armed services from biological warfare agents. Our Engagement: With sixteen other experts, I was appointed to the Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasure Again Biological Warfare
The Problem: Stroke is the third leading cause of death in the United States and the leading cause of adult disability. While experts agree that stroke must be treated as a medical emergency and despite proven preventative therapies, stroke care in the United States has limited acute treatment options, low public awareness and inconsistent response
The Problem: Yes, it was the last millennium. At the time, there were serious fears in government and the private sector about the implications for the ‘turn of the era’ and our increasingly computerized society. Health care companies providing medications were concerned that their operations would be usurped by government agencies. Our Engagement: We were
The Problem: The Child Health and Human Development Institute of the National Institutes of Health sought to increase the level of R&D in medicines for children. At the time, most medications had not yet been tested in children and as a result, children were treated “off Label.” It was imperative to improve pediatric pharmacologic research.
The Problem: There are many types of viral hepatitis and thanks to vaccines and medicines is more preventable and treatable than ever before. There is a gap, however, between the opportunities for prevention and treatment and those practices within health care. In addition, there is a need for new vaccines for types of hepatitis that
The Problem: Veteran’s organizations focus on many needs of returning soldiers, including their need for health care. The veteran’s community had never met together, however, to discuss the health concerns of veterans. Our Engagement: We were engaged to help bring all veterans organizations together to plan and conduct the first-ever summit meeting on veteran’s health.
The Problem: Patient advocates voiced concerns about the inappropriate disclosure of patients’ personal information. Our Engagement: We were engaged by several organizations in the arena of pharmaceutical care to analyze the concerns of those advocates and propose solutions. Our Actions: We not only tracked the views of advocacy organizations, but also those of governments and
The Problem: The State of New Jersey is home to global biopharmaceutical companies and major research and teaching institutions. It is poised to develop as a Life Sciences Supercluster and become a national leader in bioscience research, but only if government, academia and industry collaborate. Our Engagement: We were engaged to help the various collaborators
The Problem: Draft Guidelines produced by the World Health Organization (WHO) would hinder – and possibly even prevent – pharmaceutical companies from donating medicines to organizations who served the needs of the poor in developing nations. Our Engagement: We were engaged initially to develop an alternative to WHO’s approach. We were asked, as well, to